Haemonetics Corporation (NYSE:HAE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Haemonetics Corporation (NYSE:HAE) have received an average rating of “Moderate Buy” from the eleven analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $77.1111.

HAE has been the subject of several recent analyst reports. Citigroup increased their price target on Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday. Mizuho lowered their price target on Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Weiss Ratings downgraded Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, May 21st. Finally, Robert W. Baird set a $67.00 price objective on Haemonetics in a report on Friday, May 8th.

Haemonetics Stock Up 1.5%

Shares of Haemonetics stock opened at $68.02 on Friday. Haemonetics has a 1 year low of $47.31 and a 1 year high of $87.32. The business has a 50-day moving average of $58.95 and a two-hundred day moving average of $67.42. The company has a market capitalization of $3.09 billion, a P/E ratio of 33.67, a price-to-earnings-growth ratio of 1.35 and a beta of 0.53. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The company had revenue of $346.35 million during the quarter, compared to the consensus estimate of $336.83 million. During the same period in the prior year, the company earned $1.24 earnings per share. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, equities analysts predict that Haemonetics will post 5.23 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of HAE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Haemonetics by 3.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after buying an additional 971 shares in the last quarter. Caxton Associates LLP bought a new position in shares of Haemonetics during the first quarter worth about $216,000. United Services Automobile Association bought a new position in shares of Haemonetics during the first quarter worth about $212,000. Empowered Funds LLC grew its holdings in shares of Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after buying an additional 372 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after buying an additional 9,051 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.